<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Shao Q</submitter><funding>U.S. Department of Health &amp; Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics)</funding><funding>NCI NIH HHS</funding><funding>U.S. Department of Health &amp;amp; Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute</funding><pagination>899-908</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11976298</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>39(4)</volume><pubmed_abstract>Activating mutations in STAT6 are common in Follicular Lymphoma (FL) and transformed FL and various other B cell lymphomas. Here, we report RNA-seq based gene expression data on normal human lymph node derived B lymphocytes (NBC; N = 6), and primary human FL WT (N = 11) or mutant (N = 4) for STAT6 before and after ex vivo stimulation with IL4. We found that STAT6 mutants result in broad based augmentation of IL4-induced gene expression. Unexpectedly, in FL with WT STAT6 we measured reduced baseline and IL4-induced gene expression levels when compared with NBC lymphocytes or FL with STAT6 mutations. We tracked the attenuated IL4/JAK/STAT6 response to co-existing CREBBP mutations and experimentally verified that intact CREBBP is required for the induction of many IL4-induced genes. One of th</pubmed_abstract><journal>Leukemia</journal><pubmed_title>STAT6 mutations compensate for CREBBP mutations and hyperactivate IL4/STAT6/RRAGD/mTOR signaling in follicular lymphoma.</pubmed_title><pmcid>PMC11976298</pmcid><funding_grant_id>P30 CA046592</funding_grant_id><funding_grant_id>R01CA260677</funding_grant_id><funding_grant_id>R01 CA260677</funding_grant_id><pubmed_authors>Shedden K</pubmed_authors><pubmed_authors>Malek IA</pubmed_authors><pubmed_authors>Shao Q</pubmed_authors><pubmed_authors>Bedi K</pubmed_authors><pubmed_authors>Malek SN</pubmed_authors></additional><is_claimable>false</is_claimable><name>STAT6 mutations compensate for CREBBP mutations and hyperactivate IL4/STAT6/RRAGD/mTOR signaling in follicular lymphoma.</name><description>Activating mutations in STAT6 are common in Follicular Lymphoma (FL) and transformed FL and various other B cell lymphomas. Here, we report RNA-seq based gene expression data on normal human lymph node derived B lymphocytes (NBC; N = 6), and primary human FL WT (N = 11) or mutant (N = 4) for STAT6 before and after ex vivo stimulation with IL4. We found that STAT6 mutants result in broad based augmentation of IL4-induced gene expression. Unexpectedly, in FL with WT STAT6 we measured reduced baseline and IL4-induced gene expression levels when compared with NBC lymphocytes or FL with STAT6 mutations. We tracked the attenuated IL4/JAK/STAT6 response to co-existing CREBBP mutations and experimentally verified that intact CREBBP is required for the induction of many IL4-induced genes. One of th</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Apr</publication><modification>2026-05-02T14:32:32.723Z</modification><creation>2025-07-06T03:04:31.289Z</creation></dates><accession>S-EPMC11976298</accession><cross_references><pubmed>39910284</pubmed><doi>10.1038/s41375-025-02525-6</doi></cross_references></HashMap>